SG10201706265PA - Novel compounds and compositions for targeting cancer stem cells - Google Patents

Novel compounds and compositions for targeting cancer stem cells

Info

Publication number
SG10201706265PA
SG10201706265PA SG10201706265PA SG10201706265PA SG10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA
Authority
SG
Singapore
Prior art keywords
compositions
stem cells
novel compounds
cancer stem
targeting cancer
Prior art date
Application number
SG10201706265PA
Other languages
English (en)
Inventor
David Leggett
Chiang Jia Li
Youzhi Li
Wei Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of SG10201706265PA publication Critical patent/SG10201706265PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
SG10201706265PA 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells SG10201706265PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19

Publications (1)

Publication Number Publication Date
SG10201706265PA true SG10201706265PA (en) 2017-08-30

Family

ID=50940329

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201502079VA SG10201502079VA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells
SG10201706265PA SG10201706265PA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells
SG10201704745UA SG10201704745UA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201502079VA SG10201502079VA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704745UA SG10201704745UA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Country Status (11)

Country Link
EP (2) EP3108750B1 (pt)
JP (11) JP2014098050A (pt)
CN (3) CN106860443A (pt)
CA (3) CA2959951A1 (pt)
DK (1) DK3108750T3 (pt)
ES (1) ES2689928T3 (pt)
HU (1) HUE066482T2 (pt)
NZ (2) NZ701237A (pt)
PT (1) PT2547205T (pt)
RU (2) RU2657750C1 (pt)
SG (3) SG10201502079VA (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
CA2959951A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
BR112012023660B8 (pt) * 2010-03-19 2021-05-25 Boston Biomedical Inc usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
KR20180015195A (ko) * 2015-06-03 2018-02-12 보스톤 바이오메디칼, 인크. 암의 치료에 사용하기 위한 암 줄기능 저해제 및 면역치료제를 포함하는 조성물
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP6751658B2 (ja) 2016-11-15 2020-09-09 クラリオン株式会社 音声認識装置、音声認識システム
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのstat3シグナル伝達の阻害
AU2003275056A1 (en) * 2002-09-17 2004-04-08 Arqule, Inc. Novel lapacho compounds and methods of use thereof
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
JP2009510121A (ja) * 2005-09-30 2009-03-12 スミスクライン・ビーチャム・コーポレイション 医薬組成物
EP1860126A1 (en) * 2006-05-26 2007-11-28 INEOS Manufacturing Belgium NV Polyolefin powder
CN101854802B (zh) * 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
CN104530061B (zh) * 2008-07-08 2017-05-10 贝达药业股份有限公司 埃克替尼盐酸盐晶型、药物组合物和用途
JP5602935B2 (ja) * 2010-03-19 2014-10-08 ボストン バイオメディカル, インコーポレイテッド がん幹細胞を標的とするための新規の化合物および組成物
CA2959951A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
BR112012023660B8 (pt) * 2010-03-19 2021-05-25 Boston Biomedical Inc usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer

Also Published As

Publication number Publication date
CN104016951A (zh) 2014-09-03
JP2014098050A (ja) 2014-05-29
JP2020063308A (ja) 2020-04-23
HUE066482T2 (hu) 2024-08-28
JP5993390B2 (ja) 2016-09-14
JP2020114888A (ja) 2020-07-30
CA2993363A1 (en) 2011-09-22
JP2018002744A (ja) 2018-01-11
NZ701237A (en) 2016-04-29
CA2959931A1 (en) 2011-09-22
SG10201502079VA (en) 2015-06-29
JP2015232037A (ja) 2015-12-24
NZ712826A (en) 2017-03-31
RU2657750C1 (ru) 2018-06-15
SG10201704745UA (en) 2017-07-28
RU2015142279A (ru) 2018-12-28
JP2014098048A (ja) 2014-05-29
CN107311969B (zh) 2022-01-28
EP3108750A1 (en) 2016-12-28
CA2959951A1 (en) 2011-09-22
JP2022020002A (ja) 2022-01-27
EP3108750B1 (en) 2018-07-04
DK3108750T3 (en) 2018-10-22
EP3295796A1 (en) 2018-03-21
CN106860443A (zh) 2017-06-20
CN104016951B (zh) 2016-07-13
CN107311969A (zh) 2017-11-03
RU2015142279A3 (pt) 2019-02-26
JP2016222723A (ja) 2016-12-28
JP2014098049A (ja) 2014-05-29
JP2018115209A (ja) 2018-07-26
PT2547205T (pt) 2024-05-27
JP2015098489A (ja) 2015-05-28
ES2689928T3 (es) 2018-11-16
JP6246169B2 (ja) 2017-12-13

Similar Documents

Publication Publication Date Title
EP2547334A4 (en) NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS
HK1243746A1 (zh) 組合物
RS65536B1 (sr) Novi postupci za ciljanje matičnih ćelija kancera
HK1178797A1 (en) Sunblock composition
EP2593098A4 (en) METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
SG10201706265PA (en) Novel compounds and compositions for targeting cancer stem cells
GB201002983D0 (en) Nutritinal composition
GB201009549D0 (en) Compositions
GB201119596D0 (en) Improved compositions
GB201009546D0 (en) Compositions
GB201010954D0 (en) Compositions
GB201002861D0 (en) Compositions
EP2771014A4 (en) PHARMACEUTICAL COMPOSITION FOR ERADICATING CANCER STEM CELLS
PL2534242T3 (pl) Polepszona kompozycja do hamowania proliferacji komórek nowotworowych
EP2625231A4 (en) INK PRESERVATIVE COMPOSITIONS
WO2011116344A9 (en) Targeting cancer stem cells
IL214545A0 (en) Compositions and methods for visualizing and eliminating cancer stem cells
IL225952A0 (en) preparations@rokkhot
GB201014591D0 (en) Compositions
GB201005927D0 (en) Improved composition
ZA201303199B (en) Herbicicdal composition
GB201007790D0 (en) Compositions
EP2575743A4 (en) WELD-INHIBITING COMPOSITIONS
PL2545016T3 (pl) Kompozycja zawierająca fosforan hemipotasowy
GB201019606D0 (en) Compositions